Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors

#2822

Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.

Aim(s): To describe treatment outcomes in secondary panNET G3.

Materials and methods: A single-center retrospective cohort study at Uppsala University Hospital that included all patients with secondary panNET G3 undergoing sequential systemic monotherapy. Grading was based on the WHO 2017 classification of panNEN. Treatment strategies were characterized and radiological responses were evaluated using RECIST 1.1 criteria.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mollazadegan K, Botling J, Welin S, Eriksson B, Skogseid B,

Keywords: pancreas, neuroendocrine tumor, treatment,

To read the full abstract, please log into your ENETS Member account.